Bacterial Inclusion Bodies for Anti-Amyloid Drug Discovery: Current and Future Screening Methods
- 20 May 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 20 (6) , 563-576
Abstract
Amyloid aggregation is linked to an increasing number of human disorders from nonneurological pathologies such as type-2 diabetes to neurodegenerative ones such as Alzheimer or Parkinson’s diseases. Thirty-six human proteins have shown the capacity to aggregate into pathological amyloid structures. To date, it is widely accepted that amyloid folding/aggregation is a universal process present in eukaryotic and prokaryotic cells. In the last decade, several studies have unequivocally demonstrated that bacterial inclusion bodies – insoluble protein aggregates usually formed during heterologous protein overexpression in bacteria – are mainly composed of overexpressed proteins in amyloid conformation. This fact shows that amyloid-prone proteins display a similar aggregation propensity in humans and bacteria, opening the possibility to use bacteria as simple models to study amyloid aggregation process and the potential effect of both anti-amyloid drugs and pro-aggregative compounds. Under these considerations, several in vitro and in cellulo methods, which exploit the amyloid properties of bacterial inclusion bodies, have been proposed in the last few years. Since these new methods are fast, simple, inexpensive, highly reproducible, and tunable, they have aroused great interest as preliminary screening tools in the search for anti-amyloid (beta-blocker) drugs for conformational diseases. The aim of this mini-review is to compile recently developed methods aimed at tracking amyloid aggregation in bacteria, discussing their advantages and limitations, and the future potential applications of inclusion bodies in anti-amyloid drug discovery.Keywords
Funding Information
- Generalitat de Catalunya (2017SGR106)
- Ministerio de Economía y Competitividad and the Agencia Estatal de Investigación of Spain (CTQ2017-88446-R, SAF2017-82771-R)
This publication has 81 references indexed in Scilit:
- Disaggregation of Amyloid Plaque in Brain of Alzheimer’s Disease Transgenic Mice with Daily Subcutaneous Administration of a Tetravalent Bispecific Antibody That Targets the Transferrin Receptor and the Abeta Amyloid PeptideMolecular Pharmaceutics, 2013
- Using bacterial inclusion bodies to screen for amyloid aggregation inhibitorsMicrobial Cell Factories, 2012
- Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer DiseaseJournal of Biological Chemistry, 2011
- Bacterial Inclusion Bodies Contain Amyloid-Like StructurePLOS Biology, 2008
- Localization of Functional Polypeptides in Bacterial Inclusion BodiesApplied and Environmental Microbiology, 2007
- Alzheimer's disease, the nematode Caenorhabditis elegans, and ginkgo biloba leaf extractLife Sciences, 2006
- Mutagenesis of the central hydrophobic cluster in Aβ42 Alzheimer's peptideThe FEBS Journal, 2006
- Solubilization of aggregated proteins by ClpB/DnaK relies on the continuous extraction of unfolded polypeptidesFEBS Letters, 2004
- Network biology: understanding the cell's functional organizationNature Reviews Genetics, 2004
- Proteolytic digestion of bacterial inclusion body proteins during dynamic transition between soluble and insoluble formsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1999